Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control

This case report discusses the use of upadacitinib, a selective JAK1 inhibitor, in treating a 52-year-old male with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome. Over 12 weeks of treatment with 15 mg of upadacitinib daily, the patient experienced significant improvements in all conditions: the Severity of Alopecia Tool (SALT) score decreased from 15 to 0.9, vitiligo lesions stabilized, spinal mobility increased, and asthma and nasal symptoms reduced. Additionally, serum total IgE levels decreased. A transient liver function abnormality was observed but resolved with monitoring. The findings suggest upadacitinib's effectiveness and manageable safety profile for complex immune comorbidities, supporting the strategy of targeting upstream common pathways.